E-GEOD-2470
Ontology highlight
ABSTRACT:
OTHER RELATED OMICS DATASETS IN: PRJNA91183
PROVIDER: E-GEOD-2470 | ExpressionAtlas | 2015-09-16
REPOSITORIES: ExpressionAtlas
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| E-GEOD-2470-analysis-methods.tsv | Tabular | |||
| E-GEOD-2470-atlasExperimentSummary.Rdata | Rdata | |||
| E-GEOD-2470-configuration.xml | Xml | |||
| E-GEOD-2470-percentile-ranks.tsv | Tabular | |||
| E-GEOD-2470.condensed-sdrf.tsv | Tabular |
Items per page: 5 1 - 5 of 87 |
Similar Datasets
Project description:Transcription profiling of rat penis samples from animals with diabetes-induced erectile dysfunction
2014-07-03 | E-GEOD-2457 | ExpressionAtlas
Project description:Transcription profiling of human leukemia cell lines treated with sera from Type I diabetes patients to investigate sera-induced transcriptional signatures.
2025-01-24 | E-GEOD-24147 | ExpressionAtlas
Project description:Transcription profiling by array of skeletal muscle in TypeII diabetes patients
2025-01-24 | E-GEOD-19420 | ExpressionAtlas
Project description:Transcription profiling of human brain tissue from subjects with bipolar disorder and healthy controls
2025-01-24 | E-GEOD-5388 | ExpressionAtlas
Project description:537 million people globally suffer from diabetes. Insulin-producing beta cells are reduced in number in most people with diabetes, but the majority still have some residual beta cells. Disappointingly, none of the many diabetes drugs in common use can increase human beta cell numbers. Recently, small molecules that inhibit the kinase, Dual Tyrosine-Regulated Kinase 1A (DYRK1A), have been shown to induce immunohistochemical markers of human beta cell replication, and this is enhanced by drugs that stimulate the GLP1 receptor (GLP1R) on beta cells. However, it remains to be demonstrated whether these immunohistochemical findings translate into an actual increase in human beta cell numbers in vivo. It is also unknown whether DYRK1A inhibitors together with GLP1R agonists (GLP1RAs) affect human beta cell survival. Here, we demonstrate for the first time that combination of a DYRK1A inhibitor with exendin-4 increases actual human beta cell mass in vivo by 400-700% in diabetic and non-diabetic mice over three months, reverses diabetes in vivo, without significant alteration in human alpha cell mass. The augmentation in human beta cell mass occurs through mechanisms that include enhanced human beta cell proliferation, function, and survival. The increase in human beta cell survival is mediated in part by the islet prohormone, VGF. Taken together, these findings demonstrate the remarkable therapeutic potential and safety profile of the DYRK1A inhibitor-GLP1RA combination for diabetes treatment.
2024-06-28 | GSE249310 | GEO
Project description:Transcription profiling of human adult postmortem brain tissue from Down syndrome and healthy control subjects
2025-01-24 | E-GEOD-5390 | ExpressionAtlas
Project description:Type 1 diabetes (T1D) is an immune-mediated disease that leads to β cell dysfunction and death. However, the contribution of β cells in this process remains unclear. To understand how islet-derived pro-inflammatory signaling pathways contribute to diabetes pathogenesis, we generated inducible islet-specific Alox15 knockout mice on the NOD background. We report that islet-specific deletion of Alox15 induced a substantial increase of β-cell mass and decreased islet insulitis, and ultimately lead to a protection against spontaneous autoimmune diabetes in NOD mice. Single cell RNA-sequencing and mass spectrometry analysis revealed that islet-specific knockout of Alox15 leads to an increase of β cells expressing Pd-l1 and promotes an anti-inflammatory phenotype in myeloid cells and T cells inside the islets. Furthermore, islet- specific Alox15 deletion enhances the expansion of M2-like macrophages and regulatory T cells in the pancreatic islets and pancreatic lymph nodes. Together, these results lead to the conclusion that proinflammatory signals produced by β cells allows these cells to express immunoregulators that protects these cells of immune cell attack and promote β cell survival.
2021-02-11 | GSE166572 | GEO
Project description:Diabetes onset is accompanied with β-cell deficiency, and thus restoring functional β-cell mass is a promising therapy for those with diabetes. However, the mechanisms of β-cell mass regulation are not fully understood. Previously, we demonstrated that Sox4 is required for β-cell proliferation during prediabetes. Here, we report that Sox4 regulates β-cell mass through modulating expression of the type 2 susceptibility gene GRK5. Newly generated β-cell specific Grk5 knockout mice showed impaired glucose tolerance with reduced β-cell mass. In agreement with this phenotype, cell cycle inhibitor genes, Cdkn1a and Ccng1 were upregulated in Grk5 knockout islets. Furthermore, we found that Grk5 positively regulates β-cell mass through phosphorylation of HDAC5 and subsequent transcription of immediate early genes (IEGs) such as Nr4a1, Fosb, Junb, Arc, Egr1 and Srf. Together, these studies suggest GRK5 is linked to type 2 diabetes through regulation of β-cell mass. GRK5 could become a potential target of cell therapy to preserve functional β cells during the progression towards frank diabetes.
2023-07-31 | GSE221716 | GEO
Project description:The increase of functional β cell mass is paramount to maintain glucose homeostasis in the setting of systemic insulin resistance and/or augmented metabolic load. Understanding compensatory mechanisms that allow β cell mass adaptation may allow discovery of therapeutically actionable control nodes. In this study, we report the rapid and robust β cell hyperplasic effect in a mouse model of overfeeding-induced obesity (OIO) based on direct gastric caloric infusion. By performing RNA sequencing in islets isolated from OIO mice, we identified Sin3a as a novel transcriptional regulator of β cell mass adaptation. β cell-specific Sin3a knockout animals showed profound diabetes, due to defective acquisition of postnatal β cell mass. These findings reveal a novel regulatory pathway in β cell proliferation, and validate OIO as a model for discovery of other mechanistic determinants to β cell adaptation.
2022-11-09 | GSE199907 | GEO
Project description:The inability of the beta-cell to meet the demand for insulin brought about by insulin resistance leads to type 2 diabetes. In adults, beta-cell replication is one of the mechanisms thought to cause the expansion of beta-cell mass. Efforts to treat diabetes require knowledge of the pathways that drive facultative beta-cell proliferation in vivo. A robust physiological stimulus of beta-cell expansion is pregnancy, and identifying the mechanisms underlying this stimulus may provide therapeutic leads for the treatment of type 2 diabetes. The peak in beta-cell proliferation during pregnancy occurs on day 14.5 of gestation in mice. Using advanced genomic approaches, we globally characterize the gene expression signature of pancreatic islets on day 14.5 of gestation during pregnancy. We identify a total of 1,907 genes as differentially expressed in the islet during pregnancy. We demonstrate that the islet's ability to compensate for relative insulin deficiency during metabolic stress is associated with the induction of both proliferative and survival pathways. A comparison of the genes induced in three different models of islet expansion suggests that diverse mechanisms can be recruited to expand islet mass. The identification of many novel genes involved in islet expansion during pregnancy provides an important resource for diabetes researchers to further investigate how these factors contribute to the maintenance of not only islet mass, but ultimately beta-cell mass.
2010-06-26 | E-MTAB-120 | biostudies-arrayexpress